GSKCONS

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange�� regarding Approval of the Competition Commission of India to the proposed amalgamation of GlaxoSmithKline Consumer Healthcare Limited with Hindustan Unilever Limited. Disclosure under Regulation 30(7) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

GlaxoSmithKline Consumer Healthcare Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015In accordance with the Company��s Policy on Insider Trading, the date of commencement of closing of ��Trading Window�� shall be from December 15, 2018 and shall end 48 hours after public announcement of the Audited / Un-Audited Financial Results for the Third Quarter ended December 31, 2018.We request you to please take the above information on record.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding the Registrar & Share Transfer Agent UpdateThe Company has been informed that pursuant to Order of the Hyderabad Bench of the National Company Law Tribunal (NCLT Order), the operations of Karvy Computershare Private Limited, the Share Transfer Agents of the Company (KCPL) have been transferred to Karvy Fintech Private Limited (Karvy Fintech) with effect from November 17, 2018. The Company has been further informed that pursuant to the NCLT Order all the existing agreements to which KCPL is a party including the agr

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that�� the Board of Directors of GlaxoSmithKline Consumer Healthcare Limited (the ��Company��) in its meeting held on December 03, 2018 considered and approved a scheme of amalgamation between the Company and Hindustan Unilever Limited (��HUL��), and their respective shareholders and creditors (��Scheme��) under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013.

The Exchange has sought clarification from GlaxoSmithKline Consumer Healthcare Limited with respect to recent news item captioned "Unilever may pip Nestle to buy GSK's India unit.". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. GlaxoSmithKline Consumer Healthcare Limited has submitted their response.

The Exchange has sought clarification from GlaxoSmithKline Consumer Healthcare Limited with respect to recent news item captioned "Unilever may pip Nestle to buy GSK's India unit.". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such negotiations were taking place and b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Notice of Postal Ballot

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2018.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call UpdatesPursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, the details of Analyst / Institutional Investors Meeting to be held on Friday, November 02, 2018 is as follows: Type of Meeting Time of Event Dial - in DetailsConference Call 1200 hours (IST) India +91 22 6280 1145/ +91 22 7115 8046 Hong Kong 800 964 448 Singapore 800 101 2045 UK 0 808 101 1573 USA 1 866 746 2133The above is for your information. Please t

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call UpdatesDear Sir / Madam,In reference to our intimation dated August 09, 2018 w.r.t. Schedule of Analyst, we wish to inform you that intimation was filed in time but was inadvertently given in the wrong letter head.The details of Analyst / Institutional Investors Meeting held on Thursday, August 9, 2018 is as follows: Type of Meeting Time of Event Dial - in DetailsConference Call 1100 hours (IST) India +91 22 6280 1145/ +91 22 7115 8046 Hong Kong 800 964 448 Singap

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Change in Director(s) of the company.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

In pursuance to Regulation 44 of per SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (��LODR��) and in furtherance to our letter dated August 8, 2018, we would like to inform you that we have received the Scrutinizers�� Report containing the consolidated results of the remote e-votes received upto the August 7, 2018 (5:00 P.M.) and the voting through ballot paper received till the conclusion of the Annual General Meeting. The details of voting results, as per the Scrutinizers�� Report and as per SEBI LODR, are enclosed in the prescribed format as ��Annexure A��.Based on t

GlaxoSmithKline Consumer Healthcare Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 08, 2018. Further, the company has informed the Exchange regarding voting results.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, the details of Analyst / Institutional Investors Meeting to be held on Thursday, August 9, 2018 is as follows: Type of Meeting Time of Event Dial - in DetailsConference Call 1100 hours (IST) India +91 22 6280 1145/ +91 22 7115 8046 Hong Kong 800 964 448 Singapore 800 101 2045 UK 0 808 101 1573 USA 1 866 746 2133The above is for your information. Please t

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 08, 2018

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange, the financial results for the period ended June 30, 2018.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Change in Director(s) of the company.

The Exchange has sought clarification from GlaxoSmithKline Consumer Healthcare Limited with respect to recent news item captioned "Coca Cola plans to boost muscle with Horlicks buy". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. GlaxoSmithKline Consumer Healthcare Limited has submitted their response.

The Exchange has sought clarification from GlaxoSmithKline Consumer Healthcare Limited with respect to recent news item captioned Coca Cola plans to boost muscle with Horlicks buy. In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such negotiations were taking place and b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Change in Director(s) of the company.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2018.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 11, 2018 the Board also recommended a Dividend at the rate of Rs. 75/-per equity share of Rs. 10 each.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company shall remain closed from August 2, 2018 to August 8, 2018(both days inclusive) for the purpose of dividend and Annual General Meeting of the Company is scheduled to be held on August 08, 2018.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Date of payment of dividend

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Board meeting held on May 11, 2018.

Horlicks Limited has submitted to the Exchange a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Board meeting held on March 28, 2018.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding 'Strategic Review of Horlicks and Other Consumer Nutrition Products This is to notify that the Company notes the announcement by GlaxoSmithKline plc (GSK) of its intent to carry out a strategic review of GSK��s Horlicks and its other consumer nutrition products which will include an assessment of its 72.45% shareholding in the Company. The above may please be taken as our intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.'.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange, the financial results for the period ended 31-Dec-2017.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

GSKCONS:The Exchange had sought clarification from GlaxoSmithKline Consumer Healthcare Limited with respect to announcement dated 06-Dec-2017, regarding Change in Director(s) of the company.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment); The response of the Company is as follow- Mr Navneet Saluja has completed his MBA from Jamnalal Bajaj Institute of Management in 1987. Mr Navneet Saluja started his career with Cadbury India as a Management Trainee. He then had a long and successful stint with Gillette India. In his last role with

GSKCONS:The Exchange has sought clarification from GlaxoSmithKline Consumer Healthcare Limited with respect to announcement dated 06-Dec-2017, regarding Change in Director(s) of the company.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment); The response of the Company is awaited.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Change in Director(s) of the company.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Change in Director(s) of the company.

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2017.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

GlaxoSmithKline Consumer Healthcare Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 09, 2017. Further, the company has informed the Exchange regarding voting results.

GlaxoSmithKline Consumer Healthcare Limited has informed the Exchange thatat the Annual General Meeting of GlaxoSmithKline Consumer Healthcare Limited held on August 9, 2017 at 9.30 a.m. at Punjab Public School Auditorium, The Punjab Public School (Senior Wing), Nabha 147 201 (Punjab), the Chairman ordered voting through Ballot Paper on all the resolutions mentioned in the Notice of the Annual General Meeting. The details of the voting results of the voting through Ballot Paper at the Annual General Meeting and the remote electronic voting on all the resolutions contained in the Notice shall b

GlaxoSmithKline Consumer Healthcare Limited has submitted to the Exchange, the financial results for the period ended June 30, 2017.